Strata Skin Sciences (SSKN) Expected to Announce Earnings on Thursday

Strata Skin Sciences (NASDAQ:SSKN) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Strata Skin Sciences to post earnings of ($0.26) per share and revenue of $5.53 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Strata Skin Sciences Stock Performance

SSKN stock traded down $0.04 during trading on Wednesday, reaching $0.24. The company had a trading volume of 723 shares, compared to its average volume of 470,326. The company has a market cap of $1.42 million, a price-to-earnings ratio of -0.09 and a beta of 0.45. Strata Skin Sciences has a twelve month low of $0.12 and a twelve month high of $3.86. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95. The firm has a 50-day simple moving average of $0.67 and a 200-day simple moving average of $1.26.

Institutional Investors Weigh In On Strata Skin Sciences

A hedge fund recently bought a new stake in Strata Skin Sciences stock. Susquehanna International Group LLP bought a new position in shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.24% of Strata Skin Sciences as of its most recent SEC filing. 32.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Strata Skin Sciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.